Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$453M |
| 2 |
CELG
Celgene Corp
CELG
|
+$391M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$389M |
| 4 |
GE Aerospace
GE
|
+$378M |
| 5 |
Johnson & Johnson
JNJ
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$307M |
| 2 |
Costco
COST
|
+$279M |
| 3 |
Lowe's Companies
LOW
|
+$273M |
| 4 |
Microsoft
MSFT
|
+$230M |
| 5 |
Chevron
CVX
|
+$225M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.59% |
| 2 | Technology | 14.11% |
| 3 | Financials | 10.92% |
| 4 | Consumer Discretionary | 9.85% |
| 5 | Real Estate | 7.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
EMX
3326
DELISTED
EMX Royalty
EMX
| $174K | ﹤0.01% |
142,500
-6,700
| -4% | -$7.96K |
|
3327
Danaos Corp
DAC
$2.52B
| $173K | ﹤0.01% |
21,365
+7,872
| +58% | +$89.3K |
|
|
OBCI
3328
DELISTED
Ocean Bio-Chem Inc
OBCI
| $173K | ﹤0.01% |
52,600
-2,400
| -4% | -$7.74K |
|
3329
Nortech Systems
NSYS
$40M
| $171K | ﹤0.01% |
42,498
-3,102
| -7% | -$12.7K |
|
|
QNRX
3330
Quoin Pharmaceuticals
QNRX
$8.54M
| $171K | ﹤0.01% |
3
+2
| +200% | +$158K |
|
|
APEX
3331
DELISTED
Apex Global Brands Inc. Common Stock
APEX
| $170K | ﹤0.01% |
13,846
+6
| +0% | +$133 |
|
3332
Mind CTI
MNDO
$21M
| $169K | ﹤0.01% |
75,754
-26,846
| -26% | -$58.3K |
|
|
THMO
3333
DELISTED
ThermoGenesis Holdings, Inc. Common Stock
THMO
| $167K | ﹤0.01% |
+1,322
| New | +$167K |
|
3334
Ocean Power Technologies
OPTT
$41.5M
| $166K | ﹤0.01% |
+86,722
| New | +$220K |
|
3335
Soligenix
SNGX
$5.26M
| $163K | ﹤0.01% |
958
+147
| +18% | +$26.5K |
|
3336
ProQR Therapeutics
PRQR
$247M
| $162K | ﹤0.01% |
17,800
+2,500
| +16% | +$29.5K |
|
3337
SIFCO Industries
SIF
$169M
| $161K | ﹤0.01% |
55,800
+3,300
| +6% | +$9.61K |
|
|
XOMA
3338
DELISTED
Xoma
XOMA
| $159K | ﹤0.01% |
+10,700
| New | +$161K |
|
|
INWK
3339
DELISTED
InnerWorkings, Inc.
INWK
| $159K | ﹤0.01% |
41,700
+30,900
| +286% | +$112K |
|
3340
Immunic
IMUX
$180M
| $157K | ﹤0.01% |
1,373
+1,341
| +4,191% | +$176K |
|
3341
Atlanticus Holdings
ATLC
$1.58B
| $154K | ﹤0.01% |
38,148
+11,848
| +45% | +$41.9K |
|
3342
Edesa Biotech
EDSA
$46.8M
| $151K | ﹤0.01% |
3,062
+1,659
| +118% | +$73K |
|
|
NH
3343
DELISTED
NantHealth, Inc
NH
| $151K | ﹤0.01% |
19,187
+8,834
| +85% | +$89.9K |
|
|
XNET
3344
Xunlei
XNET
$342M
| $149K | ﹤0.01% |
56,800
-59,000
| -51% | -$182K |
|
|
NPTN
3345
DELISTED
NEOPHOTONICS CORP
NPTN
| $149K | ﹤0.01% |
35,658
-129,631
| -78% | -$683K |
|
|
SILV
3346
DELISTED
SilverCrest Metals Inc. Common Shares
SILV
| $148K | ﹤0.01% |
+36,500
| New | +$126K |
|
3347
Citizens Community Bancorp
CZWI
$205M
| $147K | ﹤0.01% |
13,600
-3,100
| -19% | -$35.4K |
|
3348
Barnwell Industries
BRN
$14.4M
| $146K | ﹤0.01% |
129,544
+8,400
| +7% | +$10.9K |
|
|
UFAB
3349
DELISTED
Unique Fabricating, Inc.
UFAB
| $146K | ﹤0.01% |
53,899
+7,503
| +16% | +$25.3K |
|
|
GSV
3350
DELISTED
Gold Standard Ventures Corp.
GSV
| $146K | ﹤0.01% |
138,000
+105,800
| +329% | +$111K |
|
Similar funds
Renaissance Technologies's Q2 2019 Portfolio in Review
As of Q2 2019, Renaissance Technologies held 3,913 positions worth $114B, up 3.3% from $110B the previous quarter. Its ten largest holdings account for 9.1% of the portfolio.
Renaissance Technologies's Q2 2019 filing shows 495 new, 1,847 increased, 1,145 reduced and 397 closed positions. Its largest new stake was Apple: 9,290,160 shares worth $460M. The largest sale was UnitedHealth, an estimated $307M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
- Renaissance Technologies's largest Q2 2019 buy was Apple: 9,290,160 shares worth $460M.
- Renaissance Technologies added most to Celgene Corp in Q2 2019, an estimated $391M increase.
- Renaissance Technologies's biggest Q2 2019 reduction was Microsoft, cutting an estimated $230M.
- Renaissance Technologies fully exited UnitedHealth in Q2 2019, selling an estimated $307M.
- Renaissance Technologies's ten largest holdings make up 9.1% of its $114B portfolio in Q2 2019.
- Renaissance Technologies opened 495 new positions and closed 397 in Q2 2019.
- Renaissance Technologies's portfolio value rose 3.3% quarter-over-quarter to $114B.
Based on Renaissance Technologies's 13F filing for Q2 2019, filed 12 Aug 2019.